Introduction {#Sec1}
============

Antifolates inhibit the synthesis and conversion of folate derivatives (FDs). Rapidly dividing cells such as cancer cells, bacteria, or malaria parasites rely heavily on the availability of folate to grow. Thus, blockade of synthesis of these factors greatly affects cell division. This feature has been exploited for the development of antifolate drugs. FDs is a generic term that consists of ten different forms of folate. The chemical structure of one of the FDs, folic acid (FA), is shown in Fig. [1](#Fig1){ref-type="fig"}, and the role of FDs has been discussed previously (Nzila et al. [@CR31],[@CR32]). Fig. 1Chemical structures of folic acid and of the antifolate drugs we analyzed

Among all the FDs, 5-methyl-tetrahydrofolate (5-Me-THF) is the most important one. It is the predominant FD in mammals, representing 80--90% of the total folate content (Belz and Nau [@CR5]; Wagner [@CR43]). The predominance of 5-Me-THF reflects its role as a cofactor in the conversion of homocysteine to methionine, which in turn is the precursor of *S*-adenosylmethionine, the methylation cofactor involved in almost 100 reactions (Priest and Bunni [@CR34]). Tetrahydrofolate (THF) is the second most represented FD in mammals (10% of the total content); it is the product of the main folate enzyme dihydrofolate reductase (DHFR; Nzila et al. [@CR31]). The FDs FA and folinic acid (FNA) are used clinically to lower the toxicity of antifolate drugs in the treatment of cancer and rheumatoid arthritis (RA; Jackson [@CR19]).

In *Plasmodium falciparum* parasites, studies have clearly demonstrated that the addition of FA or FNA decreases the activity of antifolate drugs, both in vitro and in vitro (Kinyanjui et al. [@CR21]; van Hensbroek et al. [@CR42]). Likewise, the lowering of the folate concentration in in vitro culture medium enhances the activity of antifolate antimalarial agents (Wang et al. [@CR46]). By increasing the folate derivative pools, the parasite can bypass the inhibition of folate synthesis, leading to a decrease in antifolate activity. However, the impact of the other FDs on antifolate activity has not been explored in *P*. *falciparum*. In the present paper, we explore the impact of 5-Me-THF and THF along with FA and FNA on the standard antifolates pyrimethamine (PM) and chlorcycloguanil (CCG) against *P*. *falciparum* and the anticancer antifolates methotrexate (MTX), aminopterin (AMP), and trimetrexate (TMX; Fig. [1](#Fig1){ref-type="fig"}). We have included these anticancer drugs because there have been indications that these agents are potent against malaria parasite (Elslager et al. [@CR10]; Fidock et al. [@CR13]; Walter et al. [@CR44]). Our study indicates that these anticancer drugs alone (for MTX) or in combination with 5-Me-THF (for TMX and AMP) could be used to treat malaria. The potential of MTX as an antimalarial has led us to explore the interaction of this antifolate with other antimalarial drugs.

Materials and methods {#Sec2}
=====================

FA, FNA, THF, 5-Me-THF, PM, dapsone (DDS), MTX, AMP, chloroquine (CQ), mefloquine (MFQ), primaquine (PRQ), quinine (QN), proguanil (PG), and probenecid (PBN) were purchased from Sigma Chemical Co. (Poole, UK). CCG was a gift from AstraZeneca (Cheshire, UK). Amodiaquine (AQ), desethyl-amodiaquine (DEAQ), dihydroartemisinin (DHA), piperaquine (PQ), lumefantrine (LM), pyronaridine (PRN), halofantrine (HLF), and chlorproguanil (CPG) were gifts from Professor Steve Ward, Liverpool School of Tropical Medicine, Liverpool, UK. Trimetrexate was a gift from Professor Andre Rosowsky, Dana-Farber Cancer Institute, Boston, MA, USA.

Antimalarial activity was measured in the presence of varying concentrations of each compound using radioisotopic incorporation (Sixsmith et al. [@CR37]). Results were expressed as the drug concentration required for 50% inhibition of \[^3^H\]hypoxanthine incorporation into parasite nucleic acid (IC~50~), using nonlinear regression analysis of the dose--response curve. These IC~50~ values were determined in the presence or absence of increasing concentrations of folate derivatives. Two reference *P*. *falciparum* laboratory isolates were tested: M24, a fully pyrimethamine-sensitive isolate, and V1/S, a highly pyrimethamine-resistant isolate. M24 carries a wild-type *dhfr* gene, but the V1/S isolate has four mutations at codons 108, 51, 59, and 164 in its *dhfr* gene (Nzila et al. [@CR30]). Cultures were carried out in Roswell Park Memorial Institute (RPMI) 1640 (GIBCO BRL, UK) medium supplemented with 10% (*v*/*v*) normal human serum, 25 mM bicarbonate, 2 mM glutamine**,** 25-mM 4-(2-hydroxyethyl)-1-piperazine-ethanesulfonic acid buffer, and 3.6 nM para-aminobenzoic acid. Human blood used to culture the parasites in vitro was obtained from healthy subjects and washed three times with RPMI culture medium nonsupplemented with serum.

**Synergy** Synergy analyses were carried out using V1/S isolate in RPMI medium containing folic acid at physiological concentration (23 nM). Synergy was assessed by combining MTX with another drug in the following ratios: 1:0, 0.8:0.2, 0.6:0.4, 0.4:0.6, and 0.2:0.8. Synergy was measured in vitro both geometrically by construction of isobolograms (with a minimum of five coordinates) and algebraically by calculating the sum of the minimum fractional inhibitory concentration (FIC; Berenbaum [@CR6]). Synergy is demonstrated when the FIC is \<0.5. A FIC value of \>4.0 denotes an antagonistic effect and a FIC value between 0.5 and 4.0 indicates either nonsynergistic or nonantagonistic interaction.

Results {#Sec3}
=======

Folate effect {#Sec4}
-------------

We tested the in vitro activity of the anticancer agents MTX, AMP, and TMX and the antimalarials PM and CCG in the presence of increasing concentrations of FA, the commonly used folate derivative, and THF, FNA, and 5-Me-THF, using the multidrug-resistant V1/S and the fully sensitive isolate M24. We used four folate concentrations: 0.023 μM, which is the physiological folate concentration (normal value in the human body), and concentrations representing 10 (0.23 μM), 100 (2.3 μM) and 1,000 (23 μM) times the physiological concentration. The 2.3-μM concentration is the highest concentration of folate that can be achieved in vivo when high doses of folate derivatives are administered (Barredo et al. [@CR4]).

Table S1 shows the results of FA addition on the antimalarial activity of PM and CCG using the multidrug-resistant isolate V1/S. At the physiological FA concentration (0.023 μM), the IC~50~ values of the antimalarial antifolates PM and CCG and the anticancer antifolates MTX, AMP, and TMX were 875, 12, 31, 59, and 15 nM, respectively. Increasing the concentration of FA to 0.23, 2.3 and 23 μM was associated with a significant decrease in PM and CCG activity, and this decrease in activity was proportional to the concentration of FA added to the medium (Table S1). For instance, PM and CCG were reduced by a factor of \>45 in the presence of 23 μM of FA. Surprisingly, however, the activities of MTX, AMP, and TMX were virtually unchanged at 0.23 and 2.3 μM of FA, and only a slight decrease was noticed at a concentration of 23 μM of FA, especially with TMX. Likewise, the same trend was observed against the fully sensitive isolate M24. At the physiological FA concentration, the IC~50~ values of PM, CCG, MTX, AMP, and TMX were 0.3, 0.22, 36, 48, and 4 nM, respectively (Table S[2](#MOESM2){ref-type=""}). PM and CCG activities were decreased by 2.5- to 33-fold when 0.023, 2.3, and 2.3 μM of FA were used, while the activities of AMP, MTX, and TMX remained unchanged up to 23 μM of FA (Table S[2](#MOESM2){ref-type=""}).

We have also tested the effect of THF. The activities of PM and CCG in the presence of THF at physiological folate concentrations were 797 and 10 nM, respectively (Table S1). These activities were decreased by between 5- and 100-fold at the three highest folate concentrations tested. On the other hand, MTX, AMP, and TMX activities remained unchanged (24, 68, and 4 nM, respectively) at all THF concentrations (Table S1). The same trend was observed when M24 was used (Table S2). We tested the effect of FNA, another form of folate that the parasite can salvage. Similar to previous observations, FNA does not affect the activity of MTX, AMP, and TMX, even at concentrations 500 times higher than the physiological folate concentration, unlike the effect on the antimalarials PM and CCG. The use of 5-Me-THF yielded the most surprising results. Indeed, this folate derivative, even when used at high concentration, did not change the activity of any of the tested drugs, including the antimalarials PM and CCG (Tables S1 and S2).

Synergy between MTX and sulfa drug {#Sec5}
----------------------------------

The combination of a sulfa drug, an inhibitor of dihydropteroate synthase (DHPS) and an inhibitor of DHFR, produces a synergistic inhibition of the folate pathway. To explore the mode of action of MTX further, we have tested the synergistic properties of MTX in combination with the DHPS inhibitor dapsone. All FICs were between 1 and 1.82, a clear indication that MTX does not synergize with dapsone, while FICs of the combination CCG--DDS were \<0.5 (Table [1](#Tab1){ref-type="table"}). Likewise, we did not observe any synergy between TMX and DDS, and all FICs were in the range 1.2--1.5. Table 1Activity of MTX in the presence of inhibitors of malaria dihydrofolate reductase (CCG and WR99210); inhibitors of dihydropteroate synthase (DDS), triazine-based compounds, synergizers of atovaquone (PG and CPG), quinoline, and aryl amino-alcohol related drugs (CQ, PQ, PRQ, LM, MFQ, HLF, DEAQ, and QN); the sesquiterpene dihydroartemisinin; the antifolate anticancer TMX; the benzonaphthyridine PRN and the naphthoquinone derivative, ATVCombinationDrug ratioScore1:10.8:0.20.6:0.40.4:0.60.2:0.8Sum FIC*CCG*--*DDS*0.36 ± 0.180.46 ± 0.00.40 ± 0.00.38 ± 0.00.48 ± 0.1SynergisticMTX--DDS1.0 ± 0.11.17 ± 0.361.37 ± 0.121.82 ± 0.721.78 ± 0.27Additive*ATV*--*PG*ND0.25 ± 0.00.22 ± 0.10.24 ± 0.00.28 ± 0.0SynergisticMTX--PG1.16 ± 0.231.48 ± 0.641.84 ± 01.55 ± 0.301.32 ± 0.41AdditiveMTX--CPGND0.92 ± 0.451.49 *+* 0.01.57 *+* 1.0.98 *+* 0.0AdditiveMTX--CCG1.1 ± 0.31.09 ± 0.291.06 ± 0.161.18 ± 0.121.81 ± 0.81AdditiveMTX--WR99210ND1.10 ± 0.31.20 ± 0.31.37 ± 0.41.40 ± 0.5AdditiveMTX--CQND1.40 ± 0.341.48 ± 0.441.08 ± 0.181.17 ± 0.0AdditiveMTX--DHAND1.47 ± 0.21.33 ± 0.71.20 ± 0.300.84 ± 0.22AdditiveMTX--LM1.57 ± 0.181.07 *+* 0.01.77 *+* 0.251.89 *+* 0.191.82 *+* 0.0AdditiveMTX--QNND1.47 ± 0.411.73 ± 0.241.56 ± 0.311.36 ± 0.0AdditiveMTX--TMXND1.0 ± 0.11.33 ± 0.01.35 ± 0.01.43 ± 0.0AdditiveMTX--PRQND1.23 ± 0.21.34 ± 0.11.61 ± 0.41.14 ± 0.1AdditiveMTX--HLFND2.36 ± 0.02.32 ± 1.11.59 ± 0.51.03 ± 0.2AdditiveMTX--DEAQND1.39 ± 0.91.14 ± 0.30.87 ± 0.51.21 ± 0.1AdditiveMTX--MFQND1.90 ± 0.71.67 ± 0.81.40 ± 0.91.38 ± 1.2AdditiveMTX--ATVND1.26 ± 0.21.63 ± 0.01.15 ± 0.31.58 ± 0AdditiveMTX--PRNND3.52 ± 1.23.24 ± 1.63.14 ± 0.43.36 ± 1.0Additive?MTX--PQND2.40 ± 0.33.00 ± 0.33.33 ± 0.11.58 ± 0.1Additive?CCG--DDS and ATV--PG were used as control synergistic combinations. Data are represented as the total fractional inhibitory concentration. Synergy is demonstrated when the FIC is \<0.5. A FIC value of \>4.0 denotes an antagonistic effect and a FIC value between 0.5 and 4 indicates either nonsynergistic or nonantagonistic interaction*CCG* Chlorcycloguanil, *DDS* dapsone, *MTX* methotrexate, *ATV* atovaquone, *PG* proguanil, *CPG* chlorproguanil, *WR99210* Walter Reed compound 99210, *CQ* chloroquine, *DHA* dihydroartemisinin, *LM* lumefantrine, *QN* quinine, *TMX* trimetrexate, *PRQ* primaquine, *HLF* halofantrine, *DEAQ* desethyl-amodiaquine, *MFQ* mefloquine, *PRN* pyronaridine

Probenecid effect {#Sec6}
-----------------

Lastly, we tested the effect of PBN on the activity of anticancers MTX and TMX in *P*. *falciparum.* As part of our previous work, we have demonstrated that PBN increases the in vitro activity of antifolates, and this increase is associated with a decrease in folate uptake (Nzila et al. [@CR30]). We assessed the effect of PBN on the activity of MTX and the results are summarized in Fig. [2](#Fig2){ref-type="fig"}. PBN alone is a very weak antimalarial with a mean IC~50~ \> 1,500 μM against V1/S parasites. We have tested the effect of noninhibitory concentrations of 50, 100, and 150 μM PBN on the activity of MTX, TMX, and PM. The PM IC~50~ against V1/S was 1,200 nM, and this IC~50~ decreased by a factor between 2.5 and 5 as PBN concentration increased from 50 to 150 μM; however, MTX and TMX IC~50~ remained unchanged (at around 30 and 7 nM, respectively). The data clearly show the absence of a PBN effect on MTX and TMX in *P*. *falciparum*. Fig. 2Effect of probenecid (*PBN*) on the activity of PM, MTX, and TMX. *Y* axis represents the percentage decrease in IC~50~ in the presence of PBN. One hundred percent (*100*%) represents the IC~50~ in the absence of PBN. In the absence of PBN, the MTX, TMX, and PM IC~50~ values were 30, 7, and 1,200 nM, respectively

Synergy of MTX with other antimalarials {#Sec7}
---------------------------------------

We also explored the in vitro interaction of MTX with existing antimalarials by assessing its activity in the presence of (1) inhibitors of malaria dihydrofolate reductase (CCG and Walter Reed compound 99210); (2) triazine-based compounds, synergizers of atovaquone (ATV; PG and CPG), quinoline, and aryl amino-alcohol-related drugs (CQ, PQ, LM, MFQ, HLF, DEAQ, QN, and PRQ); (3) the antifolate anticancer TMX; (4) the sesquiterpene DHA; (5) the benzonaphthyridine PRN; and (6) the naphthoquinone derivative ATV. We used two synergistic combinations as controls: CCG and DDS (see previous section) and ATV and PG. Triazine compounds (PG) synergize with inhibitors of electron transport to the cytochrome bc1 complex (ATV; Jones and Ward [@CR20]; Nzila [@CR29]). The data are summarized in Table [1](#Tab1){ref-type="table"}. The combinations of CCG--DDS and ATV--PG were synergistic, as one would predict, with total FIC \< 0.5. All of the tested MTX combinations were additive (except two), with the FIC value falling between 0.9 and 1.6, a clear indication that the activity of MTX is neither decreased nor increased in the presence of any of these drugs. However, the total FIC of the combination of MTX with PNR was between 3.14 and 3.52, and two out of the four total FIC values of MTX with PQ (at ratios of 0.4:0.6 and 0.6:04) were 3.00 and 3.15. These values are closer to 4, the cutoff point used to identify antagonistic combinations, an indication that PNR and PQ may antagonize MTX activity.

Discussion {#Sec8}
==========

Our data clearly indicate that malaria folate metabolism has features different from those in human. Indeed, the antimalarial activity of the anticancer drugs were not decreased by FA, FNA, and THF. All of these forms of folate increase the concentrations of dihydrofolate and THF, the substrate and the product of DHFR reactions, respectively. Under these conditions, one would expect the activity of the inhibitors of DHFR to decrease. This is what we observed with the standard antimalarial antifolates PM and CCG but not with the anticancers MTX, AMP, and TMX. Yet, evidence indicates that these anticancer drugs, at least MTX, target malaria DHFR. Indeed, kinetics studies on purified plasmodial DHFR have demonstrated that MTX binds efficiently to *P*. *falciparum* and *Plasmodium vivax* DHFR (Tahar et al. [@CR40]; Toyoda et al. [@CR41]), and transfection of malaria parasite with human DHFR has further demonstrated that the antimalarial activity of MTX is primarily borne by the inhibition of DHFR (Fidock et al. [@CR13]). Thus, we would expect that addition of folate derivative would decrease the activity of these anticancer drugs in *P*. *falciparum*. In addition, there is evidence that MTX uses folate receptor--transporters to enter into the cell (Wang et al. [@CR47]); thus, the addition of FD would lower MTX transport, leading to a decrease in MTX activity. However, even at high concentrations, FDs do not decrease MTX activity. Clearly, further studies are required to understand the absence of the "folate effect" against these anticancer antifolates.

The most unexpected effect was observed with 5-Me-THF. The use of this folate derivative did not change the activity of any of the drugs we tested, including the antimalarials. 5-Me-THF is utilized to synthesize methionine, and this reaction generates THF, the product of DHFR reaction and this THF would modulate the activity of antifolates as has been clearly demonstrated in mammalian cells (Dudman et al. [@CR9]; Etienne et al. [@CR11]; Hilton et al. [@CR17]; Mini et al. [@CR27]; Reggev and Djerassi [@CR35]). Our data indicate that either 5-Me-THF is not transported into the parasite cell or that the *de novo* methionine pathways may not efficiently exist in the parasite. It is well established that the parasite obtains its amino acid supply, including methionine, from hemoglobin degradation. Thus, under these conditions, the parasite may not need to synthesize it de novo, though studies have indicated that the methionine de novo pathway may exist in *P*. *falciparum*, (Asawamahasakda and Yuthavong [@CR2]; Krungkrai et al. [@CR23]). However, because the parasite can obtain this amino acid from hemoglobin degradation or exogenous medium (Lew et al. [@CR25]), this pathway can be of relative importance, a possibility that has already been proffered (Nzila et al. [@CR31]).

Because the addition of FA, FNA, and especially 5-Me-THF does not decrease the activity of the anticancer drugs, these folate derivatives could be used as adjuvants to increase the antifolate therapeutic index. For instance, we propose to use 5-Me-THF in combination with TMX to treat malaria. This folate derivative would protect the host against drug toxicity while it will not negate the antimalarial activity of these anticancer drugs. For instance, the same rational has been developed with the combination TMX + FNA in the treatment of *Pneumocystis jiroveci* infection (an opportunistic infection commonly found with human immunodeficiency virus infection). TMX is a potent drug against *P*. *jiroveci* and this microorganism cannot transport folate derivatives; as a result, the combination of TMX + FNA is as potent as TMX alone (Walzer et al. [@CR45]). These observations led scientists to propose the use of TMX + FNA to treat *P*. *jiroveci* infection. This combination is safe, and it is now the mainstay of *P*. *jiroveci* treatment (Amsden et al. [@CR1]; Fulton et al. [@CR14]). In fact, TMX was discovered as an antimalarial drug (Elslager et al. [@CR10]) but was developed as an anticancer because it is also active against human cells. Because TMX is potent against the malaria parasite (with IC~50~ \< 15 nM), including highly PM-resistant isolates (Table S1), and because TMX + 5-Me-THF is as potent as TMX alone, thus, TMX + 5-Me-THF could be used to treat malaria. It is interesting to note that, based on the pharmacokinetics of TMX, the dose that would be required to treat malaria would be lower than that used in the treatment of cancer or *P*. *jiroveci* infection (Marshall and DeLap [@CR26]).

We also demonstrated that MTX is potent against *P*. *falciparum* isolates with IC~50~ \< 50 nM; thus, we propose this drug could be used to treat malaria. MTX is used at high doses up to 5--12 g/m^2^ per week (130--300 mg/kg) for several weeks for the treatment of cancer (Barnhart et al. [@CR3]). This dose can yield concentrations of \>1,000 μM MTX, which can have life-threatening toxicity (Barnhart et al. [@CR3]). On the other hand, a low dose of MTX (LD-MTX; 0.1 to 0.35 mg/kg (7.5 to 25 mg per adult)) is used for the treatment of RA on a chronic basis, for up to 5 years. At this dose, MTX is safe and increasingly becoming the mainstay in the treatment of RA in the Western world (Borchers et al. [@CR7]; Cronstein [@CR8]; Ostor [@CR33]; Suzuki et al. [@CR38]; Swierkot and Szechinski [@CR39]). LD-MTX is also becoming the drug of choice for the treatment of arthritis in children and multiple sclerosis, and under this regime, MTX is safe and well tolerated, (Niehues and Lankisch [@CR28]; Gray et al. [@CR15], [@CR16]; Krishna Sumanth et al. [@CR22]).

All this information has led us to propose the use of LD-MTX in the treatment of malaria. The proof of the concept that LD-MTX can be used to treat malaria in humans has already been provided. Indeed, two small clinical trials have demonstrated that doses as low as 2.5 mg per day for 3--5 days are effective to treat malaria infection in humans (Sheehy and Dempsey [@CR36]; Wildbolz [@CR48]). However, MTX has not come into widespread use because of concerns over toxicity (Ferone [@CR12]; Laing [@CR24]). At the time the aforementioned clinical trials were carried out (which was in the 1970s), no information was available on the safety of LD-MTX. LD-MTX has been widely used for the treatment of arthritis since the 1980s, and its safety has now been proven. Thus, this drug could be revived as an antimalarial. Plans for clinical trials of this drug are under way in our Unit.

We have also provided evidence that MTX does not synergize with the DHPS inhibitor dapsone, yet all DHFR inhibitors described as far synergize with inhibitor of DHPS (Nzila et al. [@CR31]) and that its activity is not increased by the addition of PBN, a well-known potentiator of antifolate activity (Hooijberg et al. [@CR18]; Nzila et al. [@CR30]). All these observations support further that some features of antifolate anticancers in *P*. *falciparum* are different from those found in mammalian cells. To further study the mechanism of action of MTX, we explored the in vitro interaction of MTX with 16 existing antimalarials. We did not find any synergistic combination; MTX has an additive effect with all tested antimalarials, except with PNR and PQ. Thus, MTX could be developed with any of the tested drugs as combination therapy, except with PNR and PQ.

We have demonstrated that *P*. *falciparum* has unique features as regards folate metabolism, and some of these features could be exploited to develop antifolate anticancers to treat malaria. For instance, TMX could be combined with 5-Me-THF as an antimalarial, and the use of MTX in the treatment of rheumatoid arthritis indicates that this drug has the potential to become an antimalarial. Plans to test MTX in vivo for the treatment of malaria are under way.
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